SCHEMBL17469274

SCHEMBL17469274

COc1cc(C)c2[nH]c(C(F)(F)F)c(C(=O)C(F)(F)F)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
HPGD P15428 2/20 0.38
MTNR1A P48039 4/20 0.37
MTNR1B P49286 3/20 0.37
BCHE P06276 1/20 0.36
NQO2 P16083 1/20 0.36
PDE10A Q9Y233 1/20 0.33
KMT2A Q03164 2/20 0.32
HDAC6 Q9UBN7 1/20 0.32
POLB P06746 1/20 0.32
DYRK1A Q13627 1/20 0.32
PDE3B Q13370 1/20 0.32
PDE3A Q14432 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
PABPC1 P11940 1/20 0.31
CRHBP P24387 1/20 0.31
CRHR2 Q13324 1/20 0.31
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17469282 0.87 NQO2 (0.45) CYP3A4HPGDMTNR1AMTNR1BBCHE
SCHEMBL17469279 0.87 ENPP3 (0.38) MTNR1AMTNR1BBCHENQO2KMT2A
SCHEMBL17469285 0.87 CFTR (0.41) MTNR1ABCHENQO2KMT2AHDAC6
SCHEMBL17469281 0.86 BCHE (0.36) MTNR1ABCHENQO2KMT2AHDAC6
SCHEMBL17469275 0.86 BCHE (0.36) CYP3A4BCHENQO2HDAC6DYRK1A
SCHEMBL19322129 0.84 GAA (0.40) CYP3A4HPGDBCHEKMT2APOLB
SCHEMBL19317471 0.83 MAPT (0.38) CYP3A4KDM4EMAPT
SCHEMBL17469286 0.82 BCHE (0.36) CYP3A4HPGDMTNR1AMTNR1BBCHE
SCHEMBL17469276 0.81 MTNR1A (0.43) HPGDMTNR1AMTNR1BBCHENQO2
SCHEMBL19317480 0.79 PDE3B (0.36) HPGDNQO2KMT2APOLBPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11147795-B2 Neuroprotective compounds and methods of use ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-10-19 US disclosed
WO-2020028060-A1 NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2020-02-06 WO disclosed
US-20190350902-A1 NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2019-11-21 US disclosed
US-10358438-B2 [3+2] annulation to produce 5-membered heterocyclic compounds ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2019-07-23 US disclosed
US-20170253580-A1 ORGANIC REACTIONS THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2017-09-07 US disclosed
WO-2016014426-A1 ORGANIC REACTIONS THE ARIZONA BOARD OF REGENTS (US) 2016-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11147795-B2 Neuroprotective compounds and methods of use RTN3, CHRNB3, ARRB1 CYP3A4 2682/4885HPGD 4533/4885MTNR1A 365/4885
US-20170253580-A1 ORGANIC REACTIONS MYC, CYP2E1, CYP3A4 CYP3A4 3/4885HPGD 2345/4885MTNR1A 3861/4885
US-20190350902-A1 NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE RTN3, CHRNB3, ARRB1 CYP3A4 2682/4885HPGD 4533/4885MTNR1A 365/4885
US-10358438-B2 [3+2] annulation to produce 5-membered heterocyclic compounds ACR, MYC, TOP1 CYP3A4 17/4885HPGD 2639/4885MTNR1A 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.